
Sign up to save your podcasts
Or


Join Robert Laugherty, PA-C, JD, a rheumatology specialist with over 16 years of experience, as he explores IL-17, a key cytokine involved in immune defense and chronic inflammatory diseases. IL-17 plays a critical role in host protection against extracellular bacteria and fungi, while its dysregulation contributes to autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
IL-17 is a family of six proteins (IL-17A to IL-17F) that function downstream of IL-23, activating epithelial cells, fibroblasts, and keratinocytes to release inflammatory cytokines and recruit neutrophils. This cascade amplifies immune responses through key signaling pathways, including NF-κB, MAPK, and C/EBP transcription factors. The persistent activation of IL-17-driven inflammation is a hallmark of several rheumatic diseases, making it a significant target for biologic therapies.
For rheumatology APPs, clinicians, and researchers, understanding the IL-17 pathway is essential for optimizing treatment strategies and advancing targeted therapies in autoimmune disease management.
Learn more by visiting RhAPP.org or accessing additional educational content on the RhAPP ACE App.
By Rheumatology Advanced Practice Providers (RhAPP)5
55 ratings
Join Robert Laugherty, PA-C, JD, a rheumatology specialist with over 16 years of experience, as he explores IL-17, a key cytokine involved in immune defense and chronic inflammatory diseases. IL-17 plays a critical role in host protection against extracellular bacteria and fungi, while its dysregulation contributes to autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
IL-17 is a family of six proteins (IL-17A to IL-17F) that function downstream of IL-23, activating epithelial cells, fibroblasts, and keratinocytes to release inflammatory cytokines and recruit neutrophils. This cascade amplifies immune responses through key signaling pathways, including NF-κB, MAPK, and C/EBP transcription factors. The persistent activation of IL-17-driven inflammation is a hallmark of several rheumatic diseases, making it a significant target for biologic therapies.
For rheumatology APPs, clinicians, and researchers, understanding the IL-17 pathway is essential for optimizing treatment strategies and advancing targeted therapies in autoimmune disease management.
Learn more by visiting RhAPP.org or accessing additional educational content on the RhAPP ACE App.

127 Listeners

116 Listeners

516 Listeners

20 Listeners